Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19036714
Ongusaha PP, et al. (2008) Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 1, ra14 19036714
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

S139-p - H2AX (human)
Modsite: GkkAtQAsQEy____ SwissProt Entrez-Gene
Orthologous residues
H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
Y27632 UV inhibit treatment-induced increase

S314-p - JIP3 (human)
Modsite: RAREKRDsRNMEVQV SwissProt Entrez-Gene
Orthologous residues
JIP3 (human): S314‑p, JIP3 (mouse): S315‑p, JIP3 iso2 (mouse): S283‑p, JIP3 iso3 (mouse): S292‑p, JIP3 (rat): S315‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry (in vitro), western blotting
Disease tissue studied:  cancer, squamous cell carcinoma
Relevant cell lines - cell types - tissues:  SCC28 (squamous)
Cellular systems studied:  cell lines
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ROCK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

S364-p - JIP3 (human)
Modsite: TRLDRtGssPTQGIV SwissProt Entrez-Gene
Orthologous residues
JIP3 (human): S364‑p, JIP3 (mouse): S365‑p, JIP3 iso2 (mouse): S333‑p, JIP3 iso3 (mouse): S342‑p, JIP3 (rat): S365‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry (in vitro), western blotting
Disease tissue studied:  cancer, squamous cell carcinoma
Relevant cell lines - cell types - tissues:  SCC28 (squamous)
Cellular systems studied:  cell lines
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ROCK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

S365-p - JIP3 (human)
Modsite: RLDRtGssPTQGIVN SwissProt Entrez-Gene
Orthologous residues
JIP3 (human): S365‑p, JIP3 (mouse): S366‑p, JIP3 iso2 (mouse): S334‑p, JIP3 iso3 (mouse): S343‑p, JIP3 (rat): S366‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mass spectrometry (in vitro), western blotting
Disease tissue studied:  cancer, squamous cell carcinoma
Relevant cell lines - cell types - tissues:  SCC28 (squamous)
Cellular systems studied:  cell lines
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ROCK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ROCK1 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, co-immunoprecipitation

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) increase ROCK1 siRNA inhibits
UV JIP3 (human) increase JIP3 siRNA inhibits
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) increase ROCK1 siRNA inhibits
UV JIP3 (human) increase JIP3 siRNA inhibits
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) increase ROCK1 siRNA inhibits
UV JIP3 (human) increase JIP3 siRNA inhibits
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) increase ROCK1 siRNA inhibits
UV JIP3 (human) increase JIP3 siRNA inhibits
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced increase constitutively active ROCK1

S63-p - Jun (human)
Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

S73-p - Jun (human)
Modsite: VGLLkLAsPELERLI SwissProt Entrez-Gene
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p, Jun (cow): S73‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
Y27632 UV inhibit treatment-induced increase
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

T19-p - MRLC2 (human)
Modsite: KKRPQRAtsNVFAMF SwissProt Entrez-Gene
Orthologous residues
MRLC2 (human): T19‑p, MRLC2 (mouse): T19‑p, MRLC2 (rat): T19‑p, MRLC2 (cow): T19‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

S20-p - MRLC2 (human)
Modsite: KRPQRAtsNVFAMFD SwissProt Entrez-Gene
Orthologous residues
MRLC2 (human): S20‑p, MRLC2 (mouse): S20‑p, MRLC2 (rat): S20‑p, MRLC2 (cow): S20‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
ROCK1 (human) ROCK1 (human) augment treatment-induced decrease constitutively active

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte), keratinocyte, U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV ROCK1 (human) no effect upon treatment-induced increase ROCK1 siRNA-no effect

S139-p - H2AX (mouse)
Modsite: GkKAsQAsQEy____ SwissProt Entrez-Gene
Orthologous residues
H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
HA-1077 ROCK1 (human) inhibit treatment-induced increase

T183-p - JNK1 (mouse)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
HA-1077 ROCK1 (human) inhibit treatment-induced increase

Y185-p - JNK1 (mouse)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
HA-1077 ROCK1 (human) inhibit treatment-induced increase

T183-p - JNK2 (mouse)
Modsite: ACTNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
HA-1077 ROCK1 (human) inhibit treatment-induced increase

Y185-p - JNK2 (mouse)
Modsite: TNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ROCK1 (human) increase
HA-1077 ROCK1 (human) inhibit treatment-induced increase